Stevens R, Simons G, Brand T, Hetterna W, Corradini L. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of the Novel Oral CCR2 Antagonist, CNTX-6970, in Healthy Volunteers [abstract]. Presented at: PAINWeek 2019, Las Vegas, Nevada, September 3-7, 2019.